

Christelle de la Fouchardière

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8278216/publications.pdf>

Version: 2024-02-01

56
papers

12,337
citations

257450

24
h-index

144013

57
g-index

61
all docs

61
docs citations

61
times ranked

14793
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. <i>Journal of Clinical Oncology</i> , 2022, 40, 382-391.	1.6	13
2	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 406.	3.7	11
3	Prognostic Value of <i>Fusobacterium nucleatum</i> after Abdominoperineal Resection for Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 1606.	3.7	7
4	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
5	Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4427.	4.1	6
6	A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein Ig-h3. <i>Journal of Personalized Medicine</i> , 2022, 12, 623.	2.5	2
7	Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study. <i>World Journal of Surgical Oncology</i> , 2022, 20, 131.	1.9	10
8	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	6.3	5
9	MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 193.	3.7	7
10	Stromal Protein-Mediated Immune Regulation in Digestive Cancers. <i>Cancers</i> , 2021, 13, 146.	3.7	18
11	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2730-2744.	0.9	4
12	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. <i>British Journal of Cancer</i> , 2021, 124, 1941-1948.	6.4	20
13	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 665-677.	10.7	110
14	Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study. <i>Cancers</i> , 2021, 13, 2966.	3.7	11
15	Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database. <i>Cancers</i> , 2021, 13, 3515.	3.7	3
16	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2359-2366.	1.6	64
17	Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. <i>European Journal of Cancer</i> , 2021, 157, 153-164.	2.8	10
18	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5562.	3.7	6

#	ARTICLE	IF	CITATIONS
19	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , 2020, 23, 73-81.	5.3	75
20	Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. <i>European Journal of Cancer</i> , 2020, 124, 91-101.	2.8	68
21	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	1.6	614
22	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2207-2218.	27.0	1,513
23	Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	1.6	233
24	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	27.0	454
25	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. , 2020, 8, e001499.		43
26	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. <i>British Journal of Cancer</i> , 2020, 123, 518-524.	6.4	16
27	High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. <i>European Journal of Cancer</i> , 2020, 135, 251-259.	2.8	102
28	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020, 147, 285-296.	5.1	56
29	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , 2020, 19, 301-310.e1.	2.3	9
30	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA4-LBA4.	1.6	150
31	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019, 115, 97-106.	2.8	29
32	Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis. <i>Oncologist</i> , 2019, 24, 1543-1548.	3.7	15
33	Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE) Tj ETQq1 1 0.784314 rgBT /Overl 658-667.	1.6	357
34	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	3.6	103
35	Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	3.7	20
36	The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF network review. <i>Bulletin Du Cancer</i> , 2019, 106, 812-819.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Stromal protein β 2ig-h3 reprogrammes tumour microenvironment in pancreatic cancer. <i>Gut</i> , 2019, 68, 693-707.	12.1	79
38	TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. <i>European Journal of Cancer</i> , 2019, 108, 41-49.	2.8	46
39	Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?. <i>Annals of Translational Medicine</i> , 2019, 7, 601-601.	1.7	0
40	Predictive factors of outcome in poorly differentiated thyroid carcinomas. <i>European Journal of Cancer</i> , 2018, 92, 40-47.	2.8	51
41	Regorafenib in the treatment of metastatic colorectal cancer. <i>Future Oncology</i> , 2018, 14, 2239-2246.	2.4	14
42	Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors. <i>Hormones and Cancer</i> , 2018, 9, 62-69.	4.9	18
43	Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report. <i>Immunotherapy</i> , 2018, 10, 831-835.	2.0	11
44	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. <i>Scientific Reports</i> , 2018, 8, 7386.	3.3	12
45	Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 1174-1179.	4.5	20
46	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. <i>European Journal of Cancer</i> , 2017, 79, 15-22.	2.8	42
47	Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. <i>Oncology Letters</i> , 2017, 13, 4917-4924.	1.8	25
48	A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. <i>European Journal of Cancer</i> , 2017, 76, 110-117.	2.8	89
49	Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCG groups (Epitopes-HPV02 study). <i>BMC Cancer</i> , 2017, 17, 574.	2.6	22
50	Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. <i>BMC Cancer</i> , 2016, 16, 412.	2.6	89
51	Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients. <i>Thyroid</i> , 2016, 26, 1085-1092.	4.5	9
52	Comment on: "Regorafenib: Start Low and Go Slow". <i>Targeted Oncology</i> , 2016, 11, 123-125.	3.6	2
53	Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. <i>Oncotarget</i> , 2016, 7, 32100-32112.	1.8	59
54	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2014, 384, 319-328.	13.7	1,295

#	ARTICLE	IF	CITATIONS
55	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2011, 364, 1817-1825.	27.0	6,140
56	Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer, 2011, 11, 469.	2.6	81